Market Overview

Allergan to Acquire MAP Pharmaceuticals for $25.00/Share

Related AGN
S&P 500 Closes Above 2,000; Dow Hits New All-Time High As Markets Continue To Rally
3 Pharma Companies That Could Deliver Breakthroughs In 'Plantibody' Technology
Allergan to Slash 13% of its Global Workforce (Fox Business)

Allergan (NYSE: AGN) and MAP Pharmaceuticals (NASDAQ: MAPP)
today jointly announced that they have entered into a definitive merger
agreement whereby Allergan will acquire 100% of the shares of MAP
Pharmaceuticals for a price of $25.00 per share. MAP Pharmaceuticals is
a biopharmaceutical company focused on developing and commercializing
new therapies in Neurology, including LEVADEX®, an orally inhaled drug
for the potential acute treatment of migraine in adults. LEVADEX® is
currently under review with the U.S. Food and Drug Administration (FDA).

The transaction, which has been unanimously approved by the boards of
directors of both companies, will be accomplished pursuant to a cash
tender offer followed by a second step merger. The per share cash

See full press release

Posted-In: News Guidance Management M&A

 

Related Articles (MAPP + AGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters